Drug intelligence / Profile preview

janthinobacterium lividum

Development stage: Unknown
Lead developer: DermBiont, Inc.
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

**Janthinobacterium lividum** is a live bacterial therapeutic being developed as the active biotherapeutic component of DermBiont's topical candidate DBI-001. In the provided clinical trial context, *J. lividum* was formulated in a gel and applied topically in escalating colony-forming unit doses to adults with atopic dermatitis colonized by *Staphylococcus aureus*, with the goal of reducing *S. aureus* abundance while assessing local tolerability. This positions the agent as a **live biotherapeutic product therapy / microbial therapy** intended to modulate the skin microbiome and provide antimicrobial activity rather than as a conventional small-molecule drug. Publicly supported indication context from the provided materials includes atopic dermatitis, while DBI-001 as a product name may also have been studied in other dermatologic settings; this annotation is specific to the active drug *janthinobacterium lividum* itself.

Other names: J. lividum

Beyond the preview

Go deeper on janthinobacterium lividum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on janthinobacterium lividum.

Explore the full profile